FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012003405> ?p ?o ?g. }

• W2012003405 endingPage "674" @default.
• W2012003405 startingPage "667" @default.
• W2012003405 abstract "The renin-angiotensin system (RAS) plays an important role in the pathogenesis of cardiovascular disease. One of the effects of the activated RAS is target-organ damage, in part due to their effects on causing hypertension. Blocking angiotensin-converting enzyme (ACE) with inhibitors has been shown to attenuate the pathological effects of the RAS. Clinical trials have shown that ACE inhibition improves outcomes in the prevention of acute myocardial infarction, lowering the morbidity and mortality in congestive heart failure, and attenuates renal dysfunction. There is recent evidence to show that angiotensin receptor blockers (ARBs) have similar efficacy to ACE inhibitors in reducing cardiovascular outcomes. The wealth of information obtained regarding the beneficial effects of RAS inhibition on clinical outcome has been focused on monotherapy with either ARB or ACE inhibition. Evidence from some trials suggests that better overall inhibition of RAS by dual therapy may improve clinical outcomes. Combination therapy has been shown to be beneficial in patients with congestive heart failure or renal disease. The Valsartan in Acute Myocardial Infarction Trial (VALIANT) trial showed equal benefit of either ARB or ACE inhibition with reduction in primary end points in postmyocardial infarction patients, but there was no further benefit from dual therapy in reducing outcomes. In the recent ONTARGET study, there was further evidence that ARBs are equal to ACE inhibitors in reducing cardiovascular events. In Ongoing Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events (ONTARGET), combined RAS blockade did not have any added benefit but resulted in increased risk of adverse outcomes. In the Candesartan in Heart Failure (CHARM) and the Valsartan Heart Failure Trial (Val-HeFT) trials of patients with severe heart failure, the addition of an ARB to an ACE inhibitor reduced cardiac mortality and lowered hospital admissions. Whether or not dual therapy is beneficial in patients with diabetic renal failure should be clarified by future studies. Overall, patients receiving dual therapy, if clinically justified, should be monitored closely for potential adverse effects." @default.
• W2012003405 created "2016-06-24" @default.
• W2012003405 creator A5045297090 @default.
• W2012003405 creator A5050936489 @default.
• W2012003405 date "2009-06-01" @default.
• W2012003405 modified "2023-09-29" @default.
• W2012003405 title "Blocking the renin–angiotensin system: dual- versus mono-therapy" @default.
• W2012003405 cites W1593069239 @default.
• W2012003405 cites W180946569 @default.
• W2012003405 cites W1821554906 @default.
• W2012003405 cites W1974814786 @default.
• W2012003405 cites W1975233458 @default.
• W2012003405 cites W1980000060 @default.
• W2012003405 cites W1984061204 @default.
• W2012003405 cites W1993013099 @default.
• W2012003405 cites W1999819607 @default.
• W2012003405 cites W2001933911 @default.
• W2012003405 cites W2002907502 @default.
• W2012003405 cites W2008372707 @default.
• W2012003405 cites W2018928665 @default.
• W2012003405 cites W2023755744 @default.
• W2012003405 cites W2044773944 @default.
• W2012003405 cites W2048011918 @default.
• W2012003405 cites W2048862063 @default.
• W2012003405 cites W2055123579 @default.
• W2012003405 cites W2056893352 @default.
• W2012003405 cites W2056976690 @default.
• W2012003405 cites W2076325467 @default.
• W2012003405 cites W2092322150 @default.
• W2012003405 cites W2093246261 @default.
• W2012003405 cites W2098780362 @default.
• W2012003405 cites W2098876918 @default.
• W2012003405 cites W2100082183 @default.
• W2012003405 cites W2100409734 @default.
• W2012003405 cites W2102979143 @default.
• W2012003405 cites W2106244081 @default.
• W2012003405 cites W2111421663 @default.
• W2012003405 cites W2116717490 @default.
• W2012003405 cites W2121061143 @default.
• W2012003405 cites W2122740041 @default.
• W2012003405 cites W2124737750 @default.
• W2012003405 cites W2125943457 @default.
• W2012003405 cites W2135038122 @default.
• W2012003405 cites W2145632481 @default.
• W2012003405 cites W2147804563 @default.
• W2012003405 cites W2149426387 @default.
• W2012003405 cites W2152798629 @default.
• W2012003405 cites W2155766891 @default.
• W2012003405 cites W2156121263 @default.
• W2012003405 cites W2157972885 @default.
• W2012003405 cites W2168907840 @default.
• W2012003405 cites W2305118939 @default.
• W2012003405 cites W2316687455 @default.
• W2012003405 cites W2418942964 @default.
• W2012003405 cites W2469805673 @default.
• W2012003405 cites W2585382523 @default.
• W2012003405 cites W2764148593 @default.
• W2012003405 cites W3021063182 @default.
• W2012003405 cites W3021250193 @default.
• W2012003405 cites W4239800685 @default.
• W2012003405 cites W4242344507 @default.
• W2012003405 cites W4245244523 @default.
• W2012003405 cites W75245760 @default.
• W2012003405 doi "https://doi.org/10.1586/erc.09.47" @default.
• W2012003405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19505282" @default.
• W2012003405 hasPublicationYear "2009" @default.
• W2012003405 type Work @default.
• W2012003405 sameAs 2012003405 @default.
• W2012003405 citedByCount "18" @default.
• W2012003405 countsByYear W20120034052012 @default.
• W2012003405 countsByYear W20120034052013 @default.
• W2012003405 countsByYear W20120034052015 @default.
• W2012003405 countsByYear W20120034052017 @default.
• W2012003405 countsByYear W20120034052020 @default.
• W2012003405 crossrefType "journal-article" @default.
• W2012003405 hasAuthorship W2012003405A5045297090 @default.
• W2012003405 hasAuthorship W2012003405A5050936489 @default.
• W2012003405 hasConcept C104849204 @default.
• W2012003405 hasConcept C126322002 @default.
• W2012003405 hasConcept C164705383 @default.
• W2012003405 hasConcept C170493617 @default.
• W2012003405 hasConcept C27016395 @default.
• W2012003405 hasConcept C2777387769 @default.
• W2012003405 hasConcept C2778198053 @default.
• W2012003405 hasConcept C2779611605 @default.
• W2012003405 hasConcept C2779716603 @default.
• W2012003405 hasConcept C2779888176 @default.
• W2012003405 hasConcept C2908929049 @default.
• W2012003405 hasConcept C500558357 @default.
• W2012003405 hasConcept C535046627 @default.
• W2012003405 hasConcept C71924100 @default.
• W2012003405 hasConcept C84393581 @default.
• W2012003405 hasConceptScore W2012003405C104849204 @default.
• W2012003405 hasConceptScore W2012003405C126322002 @default.
• W2012003405 hasConceptScore W2012003405C164705383 @default.
• W2012003405 hasConceptScore W2012003405C170493617 @default.
• W2012003405 hasConceptScore W2012003405C27016395 @default.
• W2012003405 hasConceptScore W2012003405C2777387769 @default.

• next